Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in 1998, Antisense Pharma is an innovative biotech company committed to developing novel, antisense
technology-based drugs for the treatment of cancer and other presently incurable diseases.
The antisense agents developed by the company can selectively prevent the formation of proteins causally
responsible for the development and progression of diseases like cancer. This causal approach makes antisense
therapy an innovative therapeutic modality in which diseases can be tackled at their pathogenetic origin instead of
merely combating their effects.